What grafting components produce better alveolar shape preservation following teeth extraction? A deliberate evaluate along with system meta-analysis.
  Despite the procedure performed, ascites was recurrent. Five month later, ascites spontaneously stopped growing. Paracentesis to decompress ascites was no longer required. There were 9 paracenteses performed from oophorectomy (the latest on May 23, 2019). The need for repetitive paracentesis, significantly reducing the patient's quality of life, required diagnosis for casuistic diseases. The described case is atypical because of the confusing etiology of ascites and its spontaneous cessation. Despite numerous examinations and recession of ascites, the cause of the problem is not entirely clear. PURPOSE Our purpose is to present our experience in endovascular treatment of portal vein thrombosis (PVT) during orthotopic liver transplant (OLT), initial stages, and long-term follow-up. MATERIALS AND METHODS Between May 1994 and December 2019 we performed 1246 OLTs. A total of 170 (13.64%) had some grade of PVT at the time of OLT. Since May 2000 we have performed endovascular procedures during OLT in 52 patients with PVT grade III to IV Yerdel classification. Our research consists of the 49 patients with more than 1 year of follow-up. The initial surgical technique was eversion thromboendovenectomy when the portal flow was not adequate. Intraoperative portography and endovascular treatments were taken via the graft umbilical vein, one of the recipients' mesenteric veins, the recipient portal vein, or the graft portal vein. If the cause was an obstructive or incomplete thrombus removal, venoplasty and primary stent placement were performed. RESULTS Primary stent placement was achieved in 47 of 49 patients (95.9%) adequate portal perfusion in the allograf and portal hypertension were achieved. None of the patients died during surgery or at 30 days. At long-term follow-up, 3 patients (6.1%) had a portal vein rethrombosis due to no related causes. Cumulative survival rates were 89.7%, 79.3%, and 65.5% at 1, 5, and 10 years. CONCLUSIONS Stent placement in PVT during OLT is a safe and effective procedure to resolve liver graft perfusion. It is an anatomic and physiological derivation that guarantees appropriate hepatopetal portal flow to avoid rethrombosis and portal hypertension, with low mortality and morbility. INTRODUCTION The number of pregnant kidney graft recipients receiving immunosuppressive drugs is increasing yearly. All potentially nephrotoxic and hepatotoxic immunosuppressive drugs penetrate through the placenta, which raises questions about their long-term effects on offspring. OBJECTIVES The study aimed to evaluate the influence of immunosuppressive drugs used by pregnant women after kidney transplantation on the biochemical parameters of their children. MATERIALS AND METHODS Forty children born to mothers after kidney transplantation (KTx) and 40 children of healthy mothers from the control group were included in the study. All graft-recipient mothers received immunosuppressive treatment during pregnancy. The study compared biochemical parameters, including urea, creatinine, potassium, and sodium, in both groups. RESULTS Elevated creatinine level was observed in 1 newborn in the KTx group and none of the children from the control group (P = .500). All KTx children had normal urea levels, while in the control group, 2 newborns had an increased level of urea (P = .247). Elevated potassium levels were observed in 10% of children in the KTx group and 20% of children in the control group (χ2 = 0.881; P = .348). Elevated sodium levels were observed in 22.5% of children in the KTx group and 32.5% of children in the control group (χ2 = 1.001; P =.317). No child in the KTx group had hyponatremia; mild hyponatremia was observed in 5% of children in the control group (P = .247). CONCLUSION There was no increased risk of an abnormal concentration of urea, creatinine, sodium, and potassium in the offspring of mothers after kidney transplantation using immunosuppressive drugs during pregnancy. INTRODUCTION Size mismatch between donor and recipients may negatively influence postoperative results of liver transplantation (LT). In deceased donor LT for adults, large grafts are occasionally rejected due to the fear of primary nonfunction.  https://www.selleckchem.com/products/17-AAG(Geldanamycin).html  The aim of this study is to assess the feasibility of using large liver grafts in adults undergoing deceased donor LT. METHODS We performed a retrospective study including adult patients who underwent deceased donor LT at our center between January 2006 and September 2019. Recipients with donors aged less than 18 years and those receiving split-liver grafts were excluded. Graft weight of 1800 grams was the cutoff used to divide patients in 2 groups group 1 (graft weighing  less then 1800 g) and group 2 (grafts weighing ≥ 1800 g). RESULTS A total of 806 patients were included in the study. group 1 and 2 included 722 and 84 recipients, respectively. A larger proportion of male recipients was obseved in group 2 64.8% vs 76.2% (P = .0037). Mean graft weight in group 1 and 2 was, respectively, 1348 ± 231.81 g and 1986.57 ± 165.51 g (P less then .001), which resulted in significantly higher graft weight/recipient weight ratio and graft weight/standard liver volume ratio in group 2. In group 2, there were 9 (10.71%) patients with portal vein thrombosis as well as 24 patients (28.5%) with bulky ascites and 44 grafts (52.3%) with steatosis. Primary closure of the abdominal wall was not possible in 5 patients (5.9%) from this group. Primary nonfunction was diagnosed in 14 cases (16.6%), with liver retransplantation being performed in 6 of them. Male to female sex combination occurred in 19% of LT in group 2. CONCLUSION The use of large grafts is feasible; however, proper matching between donor and recipient is paramount, especially taking into consideration graft steatosis, portal vein thrombosis and the presence of bulky ascites. BACKGROUND Secondary hyperparathyroidism usually improves after renal transplantation. When it becomes persistent, it is associated with deleterious effects on the graft, bone demineralization, fractures, calcifications, and cardiovascular events. In this study we describe the development of cases of severe hyperparathyroidism occurring after renal transplantation. OBJECTIVE To describe the behavior of the indicators of bone mineral metabolism in the renal transplantation patient with severe secondary hyperparathyroidism before transplantation, treated with or without parathyroidectomy. METHODS This is a case series study conducted between 2004 and 2017 on renal transplantation patients presenting with PTH > 800 pg/mL or who required pretransplantation parathyroidectomy.  https://www.selleckchem.com/products/17-AAG(Geldanamycin).html  RESULTS We found 36 patients with severe hyperparathyroidism, corresponding to 10.8% of transplantation recipients, with an average age of 54.5 years (±12.35). The median follow-up after transplantation was 128 months (16-159). Fourteen patients underwent parathyroidectomy before transplantation, with a median intact parathyroid hormone at the time of transplantation of 56 (3-382) pg/mL, with more episodes of hypocalcaemia and oral calcium requirement.